Opinion
Video
Examining the Evolving 3L Treatment Landscape for mCRC
Author(s):
Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.
EP: 1.Overview of Molecular Testing and Barriers in mCRC
EP: 2.Clinical Considerations for 2L Treatment Sequencing in mCRC
EP: 3.Novel Combination Regimens for 2L mCRC: Insights from ASCO 202
EP: 4.Exploring Toxicities for Second Line Treatments in mCRC
EP: 5.Existing Challenges for Patients Receiving 3L+ Therapies in mCRC
EP: 6.Factors Driving 3L Therapeutic Selection for mCRC
EP: 7.Exploring Data Outcomes From the SUNLIGHT Trial
EP: 8.Fruquintinib for mCRC: Data from the FRESCO & FRESCO-2 Studies
Now Viewing
EP: 9.Examining the Evolving 3L Treatment Landscape for mCRC
EP: 10.Additional Key Takeaways of ASCO 2024 Data in mCR
EP: 11.Future Outlooks in the Treatment of Metastatic Colorectal Cancer
- Briefly Given the latest approvals, is there a continued role for regorafenib in mCRC and how do real-world outcomes support its use? (Yisilamu P, et al. ASCO 2024. Abstract e15562)
- Dr Marshall to Panel:Let’s explore sequencing strategies for CRC in the 3L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
- Dr Marshall to Panel: How would you describe your current approach to treatment sequencing?
- Dr Benson: How do you approach treating patients with fruquintinib from FRESCO and FRESCO-2 studies according to prior treatment sequence? (Bekaii-Saab T, et al. ASCO 2024. Abstract 3579.)
- Impact of prior bevacizumab
- Dr Fakih:Please comment on recently presented data from the SUNLIGHT study and the implications on your treatment sequencing:
- Impact of prior fluoropyrimidine (Fakih, et al. ASCO GI 2024. Abstract 114)
- Impact of prior bevacizumab
- Dr Cohen: Regorafenib and/or TAS-102 sequencing (Signorelli C, et al. ASCO 2024. Abstract e15553)
Related Videos
Related Content
